Preexposure prophylaxis for HIV infection

JAMA

Volumn 308, Issue 9, 2012, Pages 865-866

  Steinbrook, Robert ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ANTIRETROVIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

ABDOMINAL PAIN; BONE DENSITY; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; PRIORITY JOURNAL; SEXUAL TRANSMISSION; SHORT SURVEY; SIDE EFFECT; WEIGHT REDUCTION; ARTICLE; DISEASE TRANSMISSION; DRUG ADMINISTRATION; DRUG APPROVAL; DRUG COMBINATION; FOOD AND DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SEXUALLY TRANSMITTED DISEASE; UNITED STATES;

ADMINISTRATION, ORAL; ANTI-RETROVIRAL AGENTS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; DRUG COMBINATIONS; HIV INFECTIONS; HUMANS; MALE; ORGANOPHOSPHORUS COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SEXUALLY TRANSMITTED DISEASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84865701068     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.9885     Document Type: Short Survey

References (10)

1. Drug details. Truvada (emitricitabine/tenofovir disoproxil fumarate) tablets, for oral use. FDA website. http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=Search.DrugDetails. July 2012. Accessed July 17, 2012.
2. Debra Birnkrant MD. Food and Drug Administration to Gilead Sciences, Inc. Supplement Approval NDA 021752/S-030. FDA website. http://www.accessdata.fda. gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label- ApprovalHistory#labelinfo. July 16, 2012. Accessed July 17, 2012.
3. Cohen MS, Chen YQ, McCauley M, et al HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
4. World Health Organization. Guidance on couples HIV testing and counselling, including antiretroviral therapy for treatment and prevention in serodiscordant couples. WHO website. http://www.who.int/hiv/pub/guidelines/ 9789241501972/en/index.html. April 2012. Accessed July 17, 2012.
5. Centers for Disease Control and Prevention (CDC). HIV in the United States: at a glance. Fact sheet, CDC website. http://www.cdc.gov/hiv/resources/ factsheets/us.htm. March 2012. Accessed July 17, 2012.
6. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.
7. Baeten JM, Donnell D, Ndase P, et al; the Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women [published online July 11, 2012]. N Engl J Med. 2012. doi:10.1056/NEJMoa1108524.
8. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana [published online July 11, 2012]. N Engl J Med. doi:10.1056/NEJMoa1110711.
9. Van Damme L, Corneli A, Ahmed K, et al; the FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women [published online July 11, 2012]. N Engl J Med. doi:10.1056/NEJMoa1202614.
10. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011;8(11):e1001123.